Trial Profile

Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sildenafil (Primary)
Indications Chronic heart failure; Diastolic heart failure; Heart failure
Focus Therapeutic Use
Acronyms RELAX

Most Recent Events

17 Nov 2020 Results (n=122) assessing immunohematologic failure identifies fibrotic phenotype in heart failure with preserved ejection fraction, presented at the American Heart Association Scientific Sessions 2020
13 May 2020 Results published in the American Journal of Medicine
16 Mar 2020 Results of post-hoc analysis assessing characterization of the clinical, physiologic, and imaging-related phenotypic differences between HFpEF patients with and without anemia, published in the American Journal of Cardiology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com